Directorio

We are doing this study to find out if an investigational drug called iptacopan (the study drug) is safe and has beneficial effects for people who have generalized Myasthenia Gravis (gMG).

This study will last about 35 weeks and has three parts: Screening, Dosing, and Follow-up. It is a double-blind study, which means neither you nor the doctors will know if you get the real medicine or a placebo. The medicine or placebo will be given as two shots under the skin. After you agree to join, treatment will start. There will be phone calls at weeks 3, 5, 7, 9, and 11 to check on your medicine and any side effects. You will have regular health checkups, physical exams, and tests like ECGs to check your heart. You will also answer short surveys about your symptoms, energy, mood, and work. You will come back at 3, 6, and 12 months for blood tests. Over the whole study, about one cup of blood will be taken. These tests will check your health, medicine levels, antibodies, and screen for diseases like HIV, hepatitis, and tuberculosis.

We are doing this study to find out if an experimental drug called CABA-201 (the study drug) is a safe and effective option for people with systemic sclerosis.

People in this study will be placed into one of two groups by chance, like flipping a coin. One group will get two medicines called DSP107 and Atezolizumab together. The other group will get a medicine called Fruquintinib by itself. Each treatment cycle lasts 4 weeks and can continue for up to 2 years. Doctors will check health and safety during the study. After the last dose, there will be a follow-up period of up to 90 days.